Breaking News on Contract Research, Manufacturing & Clinical Trials

Headlines > Clinical Development

News in brief

QPS buys stake in Bioserve to expand Phase I business


QPS has bought a majority stake in India’s Bioserve Clinical Research to bolster its Phase I and bioanalytical business.

The deal, terms of which were not disclosed, will see the Indian contract research organisation's (CRO) 100-strong staff provide early-clinical trial and bioanalysis services to both local and multinational developers at its 92-bed research unit in Hyderabad under the QPS-Bioserve India.

QPS CEO Ben Chien said: “With access to Bioserve's additional resources, our customers will have the heightened benefits of a third more phase I beds, bringing our total to 400; greater bioanalytical capacity and access to another facility.”

QPS, which offers a range of preclinical and clinical drug development services, is continuing with the growth through acquisition strategy which, last year , saw it but Netherlands-based Xendo Drug Development (XDD) to expand its European business.

QPS joins Quintiles as the second western CRO to expand its Phase I trial offering in India this week.

Subscribe to our FREE newsletter

Get FREE access to authoritative breaking news, videos, podcasts, webinars and white papers. SUBSCRIBE

Related products

Key Industry Events


Access all events listing

Our events, Events from partners...